Skip to main content

Table 1 Clinical histories of glioma patients

From: Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma

Case ID

GBM-1

AA-1

AO-1

Gender

M

F

M

Age at the time of Dx

55

51

58

KPS at the time of Dx

70%

80%

60%

Symptoms

Aphasia

Seizure

Hemi-paresis, seizure

Histology

GBM

AA

AO

Time from Dx to PBMC sampling

24 mos

153 mos

82 mos

Tumor location

Lt. hemisphere

Lt. temporal lobe

Lt. frontal lobe

Treatment

Bx

Bx

Bx, cystic aspiration

 

FEBRT

FEBRT

FEBRT

 

TMZ/CPT-11 (7 cycles)

BCNU/CDDP/VP-16 (4 cycles)

PCV (3 cycles), TMZ

Time to progression from the Dx

3 mos

No progression for 153 mos

12 mos

Current status of tumor

Progressive disease

No Gd-enhancing lesion

Progressive disease

  1. M; male, F; female, GBM; glioblastoma, AO; anaplastic oligoastrocytoma, mos; months, Bx; biopsy, Dx; diagnosis, KPS; Karnofsky performance status, FEBRT; fractionated external beam radiation therapy, Gd; Gadolinium, TMZ; temozolomide, PCV; procarbazine, lomustine and vincristine, CPT-11; irinotecan, BCNU; bischloroethylnitrosourea, CDDP; cisplatin, VP-16; etoposide.